During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...
Erika Mayer, MD, MPH, Dana-Farber Cancer Institute, discusses the exciting findings of the phase 3 lidERA study investigating ...
The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...
Sacituzumab govitecan shows improved survival and quality of life in advanced triple-negative breast cancer, outperforming ...
Are you ready to practice medicine on your own terms but feel overwhelmed by the business side of independence? You’re not ...
A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...
According to Ira Zackon, MD, a hematologist-oncologist and senior medical director at Ontada, a retrospective study of over ...
Andrew M. Brunner, MD, assistant professor of medicine at Harvard Medical School and at the Center for Leukemia at ...
The test, developed by Astrin Biosciences, utilizes deep proteomic profiling and a machine learning classifier to identify ...
Varegacestat, an investigational gamma secretase inhibitor (GSI), delivered clinically meaningful improvements in efficacy ...
Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback